Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acetazolamide + temozolomide
- Development stage
- Unknown
- Lead developer
- University of Chicago
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Acetazolamide + temozolomide is an investigational combination therapy being studied primarily for the treatment of glioblastoma and other high-grade gliomas. Acetazolamide is a carbonic anhydrase inhibitor traditionally used to treat conditions such as glaucoma, epilepsy, altitude sickness, and edema. Temozolomide is an oral alkylating agent widely used in the standard care of malignant gliomas, particularly glioblastoma multiforme. Preclinical studies have shown that acetazolamide can sensitize tumor cells to temozolomide by inhibiting BCL-3-dependent upregulation of carbonic anhydrase II, which otherwise confers resistance to temozolomide. The combination aims to overcome this resistance mechanism and improve therapeutic outcomes in patients with MGMT promoter-methylated IDH wildtype glioblastoma[4][5][8]. Early phase I clinical trials indicate that this combination is safe and tolerable when administered during the adjuvant phase of standard temozolomide therapy[2][4].
- Other names
- ACZ + TMZAcetazolamide with TemozolomideAcetazolamide and Temozolomide
02
Targets
DNACA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on acetazolamide + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acetazolamide + temozolomide.